Coronavirus (Mar 11, 2021 06:55AM ET)
© Reuters. Pfizer logo in Manhattan, New York
(Reuters) – Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) said on Wednesday that real-world data from Israel suggests that their COVID-19 vaccine is 94% effective in preventing asymptomatic infections, meaning the vaccine could significantly reduce transmission.
The companies also said the latest analysis of the Israeli data shows the vaccine was 97% effective in preventing symptomatic disease, severe disease and death. That is basically in line with the 95% efficacy Pfizer and BioNTech reported from the vaccine’s late-stage clinical trial in December.
According to the analysis, unvaccinated individuals were 44 times more likely to develop symptomatic COVID-19 and 29 times more likely to die from COVID-19 than those who had received the vaccine.
The data, collected between Jan. 17 and March 6, has not yet been peer reviewed.Pfizer/BioNTech say COVID-19 vaccine likely to prevent asymptomatic infection Add a Comment